Current Analysis

Alkermes (ALKS)

MarketCap: 4.13B

Sector: Biotechnology

Open: 29.16 Close: 29.92 Change: 0.76

alkermes plans to initiate the alixorexton narcolepsy global phase 3 program in the first quarter of 2026. the program will include exploratory patient-reported outcomes related to cognition and fatigue.

Sentiment Value: -0.25